Cargando…

Structure–Affinity Relationships and Structure–Kinetic Relationships of 1,2-Diarylimidazol-4-carboxamide Derivatives as Human Cannabinoid 1 Receptor Antagonists

[Image: see text] We report on the synthesis and biological evaluation of a series of 1,2-diarylimidazol-4-carboxamide derivatives developed as CB(1) receptor antagonists. These were evaluated in a radioligand displacement binding assay, a [(35)S]GTPγS binding assay, and in a competition association...

Descripción completa

Detalles Bibliográficos
Autores principales: Xia, Lizi, de Vries, Henk, Lenselink, Eelke B., Louvel, Julien, Waring, Michael J., Cheng, Leifeng, Pahlén, Sara, Petersson, Maria J., Schell, Peter, Olsson, Roine I., Heitman, Laura H., Sheppard, Robert J., IJzerman, Adriaan P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2017
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5734604/
https://www.ncbi.nlm.nih.gov/pubmed/29111736
http://dx.doi.org/10.1021/acs.jmedchem.7b00861
_version_ 1783287080599683072
author Xia, Lizi
de Vries, Henk
Lenselink, Eelke B.
Louvel, Julien
Waring, Michael J.
Cheng, Leifeng
Pahlén, Sara
Petersson, Maria J.
Schell, Peter
Olsson, Roine I.
Heitman, Laura H.
Sheppard, Robert J.
IJzerman, Adriaan P.
author_facet Xia, Lizi
de Vries, Henk
Lenselink, Eelke B.
Louvel, Julien
Waring, Michael J.
Cheng, Leifeng
Pahlén, Sara
Petersson, Maria J.
Schell, Peter
Olsson, Roine I.
Heitman, Laura H.
Sheppard, Robert J.
IJzerman, Adriaan P.
author_sort Xia, Lizi
collection PubMed
description [Image: see text] We report on the synthesis and biological evaluation of a series of 1,2-diarylimidazol-4-carboxamide derivatives developed as CB(1) receptor antagonists. These were evaluated in a radioligand displacement binding assay, a [(35)S]GTPγS binding assay, and in a competition association assay that enables the relatively fast kinetic screening of multiple compounds. The compounds show high affinities and a diverse range of kinetic profiles at the CB(1) receptor and their structure–kinetic relationships (SKRs) were established. Using the recently resolved hCB(1) receptor crystal structures, we also performed a modeling study that sheds light on the crucial interactions for both the affinity and dissociation kinetics of this family of ligands. We provide evidence that, next to affinity, additional knowledge of binding kinetics is useful for selecting new hCB(1) receptor antagonists in the early phases of drug discovery.
format Online
Article
Text
id pubmed-5734604
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-57346042017-12-19 Structure–Affinity Relationships and Structure–Kinetic Relationships of 1,2-Diarylimidazol-4-carboxamide Derivatives as Human Cannabinoid 1 Receptor Antagonists Xia, Lizi de Vries, Henk Lenselink, Eelke B. Louvel, Julien Waring, Michael J. Cheng, Leifeng Pahlén, Sara Petersson, Maria J. Schell, Peter Olsson, Roine I. Heitman, Laura H. Sheppard, Robert J. IJzerman, Adriaan P. J Med Chem [Image: see text] We report on the synthesis and biological evaluation of a series of 1,2-diarylimidazol-4-carboxamide derivatives developed as CB(1) receptor antagonists. These were evaluated in a radioligand displacement binding assay, a [(35)S]GTPγS binding assay, and in a competition association assay that enables the relatively fast kinetic screening of multiple compounds. The compounds show high affinities and a diverse range of kinetic profiles at the CB(1) receptor and their structure–kinetic relationships (SKRs) were established. Using the recently resolved hCB(1) receptor crystal structures, we also performed a modeling study that sheds light on the crucial interactions for both the affinity and dissociation kinetics of this family of ligands. We provide evidence that, next to affinity, additional knowledge of binding kinetics is useful for selecting new hCB(1) receptor antagonists in the early phases of drug discovery. American Chemical Society 2017-11-07 2017-12-14 /pmc/articles/PMC5734604/ /pubmed/29111736 http://dx.doi.org/10.1021/acs.jmedchem.7b00861 Text en Copyright © 2017 American Chemical Society This is an open access article published under a Creative Commons Non-Commercial No Derivative Works (CC-BY-NC-ND) Attribution License (http://pubs.acs.org/page/policy/authorchoice_ccbyncnd_termsofuse.html) , which permits copying and redistribution of the article, and creation of adaptations, all for non-commercial purposes.
spellingShingle Xia, Lizi
de Vries, Henk
Lenselink, Eelke B.
Louvel, Julien
Waring, Michael J.
Cheng, Leifeng
Pahlén, Sara
Petersson, Maria J.
Schell, Peter
Olsson, Roine I.
Heitman, Laura H.
Sheppard, Robert J.
IJzerman, Adriaan P.
Structure–Affinity Relationships and Structure–Kinetic Relationships of 1,2-Diarylimidazol-4-carboxamide Derivatives as Human Cannabinoid 1 Receptor Antagonists
title Structure–Affinity Relationships and Structure–Kinetic Relationships of 1,2-Diarylimidazol-4-carboxamide Derivatives as Human Cannabinoid 1 Receptor Antagonists
title_full Structure–Affinity Relationships and Structure–Kinetic Relationships of 1,2-Diarylimidazol-4-carboxamide Derivatives as Human Cannabinoid 1 Receptor Antagonists
title_fullStr Structure–Affinity Relationships and Structure–Kinetic Relationships of 1,2-Diarylimidazol-4-carboxamide Derivatives as Human Cannabinoid 1 Receptor Antagonists
title_full_unstemmed Structure–Affinity Relationships and Structure–Kinetic Relationships of 1,2-Diarylimidazol-4-carboxamide Derivatives as Human Cannabinoid 1 Receptor Antagonists
title_short Structure–Affinity Relationships and Structure–Kinetic Relationships of 1,2-Diarylimidazol-4-carboxamide Derivatives as Human Cannabinoid 1 Receptor Antagonists
title_sort structure–affinity relationships and structure–kinetic relationships of 1,2-diarylimidazol-4-carboxamide derivatives as human cannabinoid 1 receptor antagonists
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5734604/
https://www.ncbi.nlm.nih.gov/pubmed/29111736
http://dx.doi.org/10.1021/acs.jmedchem.7b00861
work_keys_str_mv AT xializi structureaffinityrelationshipsandstructurekineticrelationshipsof12diarylimidazol4carboxamidederivativesashumancannabinoid1receptorantagonists
AT devrieshenk structureaffinityrelationshipsandstructurekineticrelationshipsof12diarylimidazol4carboxamidederivativesashumancannabinoid1receptorantagonists
AT lenselinkeelkeb structureaffinityrelationshipsandstructurekineticrelationshipsof12diarylimidazol4carboxamidederivativesashumancannabinoid1receptorantagonists
AT louveljulien structureaffinityrelationshipsandstructurekineticrelationshipsof12diarylimidazol4carboxamidederivativesashumancannabinoid1receptorantagonists
AT waringmichaelj structureaffinityrelationshipsandstructurekineticrelationshipsof12diarylimidazol4carboxamidederivativesashumancannabinoid1receptorantagonists
AT chengleifeng structureaffinityrelationshipsandstructurekineticrelationshipsof12diarylimidazol4carboxamidederivativesashumancannabinoid1receptorantagonists
AT pahlensara structureaffinityrelationshipsandstructurekineticrelationshipsof12diarylimidazol4carboxamidederivativesashumancannabinoid1receptorantagonists
AT peterssonmariaj structureaffinityrelationshipsandstructurekineticrelationshipsof12diarylimidazol4carboxamidederivativesashumancannabinoid1receptorantagonists
AT schellpeter structureaffinityrelationshipsandstructurekineticrelationshipsof12diarylimidazol4carboxamidederivativesashumancannabinoid1receptorantagonists
AT olssonroinei structureaffinityrelationshipsandstructurekineticrelationshipsof12diarylimidazol4carboxamidederivativesashumancannabinoid1receptorantagonists
AT heitmanlaurah structureaffinityrelationshipsandstructurekineticrelationshipsof12diarylimidazol4carboxamidederivativesashumancannabinoid1receptorantagonists
AT sheppardrobertj structureaffinityrelationshipsandstructurekineticrelationshipsof12diarylimidazol4carboxamidederivativesashumancannabinoid1receptorantagonists
AT ijzermanadriaanp structureaffinityrelationshipsandstructurekineticrelationshipsof12diarylimidazol4carboxamidederivativesashumancannabinoid1receptorantagonists